Browsing: SK Biopharmaceuticals Co.

New data presented on novel orally bioavailable p300-selective degraders showing significant anti-tumor activity in preclinical models of androgen receptor (AR) positive…

These are the first in a series of presentations scheduled through the end of the year sharing advances to SK…

Renowned oncologist Yung-Jue Bang, M.D., Ph.D., chairs the distinguished 5-member Scientific Advisory Board to further advance SK Biopharmaceuticals as a…

‘Zero WiredTM’ and ‘Zero EarbudsTM’ named ‘Winners’ in the healthcare category for outstanding product design SK Biopharmaceuticals’ wearable devices earn…